Skip to main content

Center for Vaccine Development (CVD)

CVD Overview

Life-saving immunizations are one of seven great achievements in pediatric research in the past 40 years (Cheng, Monteiro et al. 2016).

Since its inception in 1974, the Center for Vaccine Development (CVD) has created and tested vaccines against cholera, typhoid fever, paratyphoid fever, non-typhoidal salmonella disease, shigellosis (bacillary dysentery), Escherichia coli diarrhea, nosocomial pathogens, tularemia, influenza, and other infectious diseases. The faculty and global staff includes molecular biologists, microbiologists, immunologists, internists, pediatricians, epidemiologists, malariologists, and biostatisticians.

Vaccines are a powerful tool to fight infectious diseases worldwide. For over 40 years, the CVD at the University of Maryland School of Medicine (UM SOM) in Baltimore, MD works domestically and internationally to develop, test, and deploy vaccines to aid the world’s underserved populations. The CVD is an academic enterprise engaged in the full range of vaccinology from basic laboratory research through vaccine development, pre-clinical and clinical evaluation, large-scale pre-licensure field studies, and post-licensure assessments.

While the main research thrust of basic research at the CVD has historically focused on bacterial enteric pathogens, rotavirus, and malaria, it has also worked more broadly on bacterial diseases, parasitic diseases, viral diseases, novel delivery systems, public health, and vaccine policy.



Dr. Neuzil brings over two decades of experience in infectious diseases and vaccine science, policy, and introduction. She’s led or been involved in pivotal vaccine trials that have influenced vaccine policy worldwide. A strong advocate for translating research results into vaccine policies, she was a key driver in the many changes in the influenza policy in the United States. Internationally, her research helped shape rotavirus vaccine policy. She is an expert on influenza, rotavirus, and RSV as well as in maternal immunization, optimizing vaccine use, and overcoming barriers to sustainable vaccine uptake in low resource settings.


Harness the power of vaccines to prevent disease and save lives in the most vulnerable populations.

Studies to facilitate meeting our mission:

  • Disease burden/epidemiology to identify the most needed vaccines
  • Molecular pathogenesis of disease-causing infections
  • Antigen discovery for the design of effective vaccines
  • Pre-clinical vaccine development to make safe and effective vaccines
  • Phase I, II, III, IV vaccine trials to evaluate the safety and efficacy in humans
  • Human challenge trials to understand the infectious process and measure vaccine efficacy
  • Immune correlates of protection to understand how best to stimulate immunity
  • Vaccine policy to introduce effective vaccines into vulnerable populations
  • Train the next generation of vaccine developers

Connect with Us:

Kathleen Neuzil, MD, MPH
CVD Director & Deputy Director of the IGH


Myron M. Levine, MD, DTPH received the 2017 Maxwell Finland Award given by the National Foundation for Infectious Diseases (NFID). This highly competitive award honors scientists who have made outstanding contributions to infectious disease research and public health.

Karen Kotloff, MD authored the article "Use of quantitative molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of the GEMS case-control study" published in the 24 September 2016 issue of The Lancet.

Kathleen Neuzil, MD, MPH co-authored the editorial Preventing Shingles and Its Complications in Older Persons published in The New England Journal of Medicine.

Wilbur Chen MD, MS served as a panelist at an NIFD press conference to kick-off influenza vaccine season.

Kathleen Neuzil, MD, MPH chaired Session C: Emerging Viruses and the Global Virus Network at the 18th Annual International Meeting of the Institute of Human Virology, Baltimore, MD, September 19, 2016.

Archived News

The Zika Virus Threat and Vaccine Trial is the Focus of a Special Panel Discussion with Dean Reece and UMSOM Faculty Experts
October 2016

NIH begins testing investigational Zika vaccine in humans
August 2016

University of Maryland School of Medicine is Center Stage in Testing National Institutes of Health Zika Vaccine
August 2016

University of Maryland researchers working on Zika vaccine
August 2016

Dr. Kathy Neuzil, CVD Director, featured on "We Need ETEC and Shigella Vaccines"
June 2016

Give to this Department